secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001628280-23-038028
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q3 net loss $0.06/sh; OCU400 shows 83% stabilization rate; OCU500 selected by NIH
--------------------------------------------------------------------------------

- Q3 2023 net loss $0.06 per share vs $0.10 year ago; cash $53.5M, down from $90.9M at Dec 2022.
- OCU400 Phase 1/2: 83% (10/12) subjects stabilized/improved in BCVA, LLVA, or MLMT; 86% (6/7) RHO subjects improved MLMT.
- Completed dosing three LCA patients including pediatric; Phase 3 for RP expected early 2024.
- OCU500 (mucosal COVID vaccine) selected by NIH/NIAID Project NextGen for clinical trial inclusion.
- OpEx $15.4M in Q3 2023 vs $23.1M in Q3 2022; R&D $6.3M, G&A $9.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/0001628280-23-038028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/ocgn-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer